ArticleBMC pulmonary medicine2024
Efficacy of transbronchial biopsy and frequency of pneumothorax in lung transplant recipients: single center experience.
Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBronchoscopy plays a critical role in the diagnosis and management of lung transplant recipients. We retrospectively evaluated the safety, complications, and efficacy of transbronchial biopsy (TBB) in detecting and grading early rejection. MATERIALS AND
methodsWe retrospectively assessed the complications associated with TBB and the adequacy of pathological diagnoses in patients who underwent lung transplantation at Koşuyolu Yüksek İhtisas Training and Research Hospital from December 1, 2016, to April 30, 2023.
resultsIn this study, we retrospectively analyzed 290 TBB procedures performed on 59 out of 94 lung transplant recipients. Of the study cohort, 72.9% (n = 43) were male, with a median age of 44.3 years. The proficiency of TBB pathology was found to be 90.7% (n = 263) for acute rejection (AR), 46.5% (n = 135) for airway inflammation, 50% (n = 145) for chronic lung allograft dysfunction (CLAD) with bronchiolitis obliterans (BO), and 89.6% (n = 260) for chronic vascular rejection. Acute rejection (AR) was detected in 23.4% (n = 68). Pneumothorax was observed in 2.07% (n = 6) of the cases. A chest tube was inserted in four patients to manage pneumothorax, while two patients received only supplemental oxygen due to minimal pneumothorax.
conclusionTBB is considered a very safe procedure when basic precautions are followed. The rate of pneumothorax, a complication associated with TBB, is low. Despite advances in immunology and genetics, TBB remains the gold standard for detecting acute rejection (AR) following lung transplantation. Given its diagnostic value, we believe that the procedure should not be avoided due to the risks of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.